Disabling cells' 'clean-up crew' could speed drug target production
en-GBde-DEes-ESfr-FR

Disabling cells' 'clean-up crew' could speed drug target production


With an unusual genetic modification which disabled cells' recycling systems, researchers found a way to make cells produce significantly larger amounts of the proteins used to discover and develop new medicines. The findings could help speed up drug development while reducing research and development costs.

Published in the journal, Cell Systems, the study addresses a persistent bottleneck in drug discovery: producing enough membrane proteins for research and development. Even though membrane proteins are the targets of around 60 percent of approved medicines, they're notoriously difficult to manufacture in useful quantities.

A team of researchers at KTH Royal Institute of Technology, in collaboration with AstraZeneca, reported significantly higher production of membrane proteins in a human cell line widely used in pharmaceutical research. They did so by disabling the pathway that cells normally rely on to recycle their own proteins. The result was increased production of three difficult-to-make target proteins – GIPR, GPR75 and P2X3 – by 30, 80 and 100 percent, respectively.

The researchers pursued the gene modification based on an unconventional hypothesis, says Johan Rockberg, professor of directed evolution at KTH. Rather than follow the well-worn path of trying to boost the production machinery in cells, the team instead disabled what Rockberg calls a cell's "clean-up crew" – or more specifically, the gene ULK1. ULK1 initiates autophagy, the process by which cells break down and recycle proteins and organelle. It's generally considered necessary for cell health, but the study shows removing the gene did no harm to the cells.

"The modified cell line produced significantly more usable protein, including several membrane proteins," Rockberg says.

"We expected cells without working autophagy to struggle," he says. "Instead, they produced more, and they did best with exactly the proteins that are usually hardest to obtain."

To understand how the cells coped with the removal of such a central part of their machinery, Alice Karlsson, doctoral student in biotechnology at KTH, took a deep dive into activity within the cells.

"The most rewarding part was seeing the effect of knocking out ULK1 and that it led to clear signs in the transcriptome with downregulation of autophagy and downstream processes," Karlsson says.

"The biggest surprise was that it also translated into higher yields of our model proteins," she says.

The finding points to autophagy as a target for host cell engineering more broadly, alongside the established approaches of strengthening the secretory machinery.

Beyond manufacturing, the observed effects on cellular metabolism and protein turnover may also be of interest where those processes play a central role, such as in neurodegenerative conditions marked by protein aggregation and impaired clearance.

The study is a collaboration between KTH and AstraZeneca, with PhD student Alice Karlsson (KTH) as first author. Melanie Dannemeyer (AZ) and Robert G. Roth (AZ) and Johan Rockberg (KTH) are corresponding authors. The work was funded by the Knut and Alice Wallenberg Foundation, AstraZeneca and the Swedish innovation agency Vinnova through GeneNova, AAVNova, CellNova and AdBIOPRO.

Alice Karlsson, Melanie Dannemeyer, Jenny Gunnarsson, Niklas Berndt Thalén, Jennifer Hicks, Magnus Lundqvist, Anna Backmark, Susanna Engberg, Carina Raynoschek, Anna-Luisa Volk, Ramy Elgendy, Michael J. Munson, Magdalena Malm, Robert G. Roth, Johan Rockberg,
ULK1 knockout increases recombinant transcript abundance and improves recombinant membrane protein expression,
Cell Systems,
2026,
101779,
ISSN 2405-4712,
https://doi.org/10.1016/j.cels.2026.101779.
Angehängte Dokumente
  • Johan Rockberg in the lab, renewing growth medium for mammalian cells cultures.
  • Overview of gene identification via small-molecule screening and effect of ULK1 KO on mRNA expression levels and recombinant protein expression levels.
  • Johan Rockberg explains how individual cells are isolated from a pool of edited cells using an instrument that employs automated imaging and a glass capillary for cell selection.
Regions: Europe, Sweden, North America, United States
Keywords: Health, Medical, Business, Medical & pharmaceutical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Referenzen

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Wir arbeiten eng zusammen mit...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement